Across TCGA pan-cancer cohorts, ANKDD1B Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated ANKDD1B data layer compared with 21 for mass-spec protein.

The strongest signal is observed in mesothelioma (MESO), where higher ANKDD1B Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated ANKDD1B expression acts as an unfavorable survival marker.

MESO and UCEC are the cancer types where ANKDD1B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
MESO	DFS	Median	III,IV	0.078	0.376	.012	9	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: ANKDD1B tumor-vs-normal RNA expression · all ANKDD1B data types